Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Biotech leader to further advance promising pipeline, including breakthrough therapy, NiCord®, in phase 3 development as a universal bone marrow transplant solution

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer (Photo: Business Wire)

JERUSALEM & CAMBRIDGE, Mass.--()--Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Julian Adams, Ph.D., as chairman and chief executive officer. Dr. Adams brings more than 30 years of drug discovery and development experience to his new role as CEO of Gamida Cell. He succeeds Yael Margolin, Ph.D., who has led the company from preclinical development to a company in phase 3 development. Dr. Margolin will remain president of Gamida Cell, continuing to lead the team in Jerusalem.

“Gamida Cell’s proprietary NAM technology platform has unprecedented potential to create curative cellular and immune therapeutics for a diverse population of patients in need,” said Dr. Adams. “I am excited to be joining such a talented team as we begin to prepare for the commercialization of our lead program, NiCord, which is currently in phase 3 clinical testing. I would like to thank Yael for her dedication throughout her time as CEO, and look forward to partnering with her to realize the potential of this promising pipeline for patients with cancer and rare genetic diseases.”

Prior to this appointment, Dr. Adams served as president and chief scientific officer at Clal Biotechnology Industries (CBI), where he oversaw the Boston office, evaluating investment opportunities and supporting portfolio companies, including Gamida Cell. Before joining CBI, he served as the president of research and development at Infinity Pharmaceuticals, where he built and led the company’s R&D efforts. Dr. Adams also served as senior vice president of drug discovery and development at Millennium Pharmaceuticals, where he played a key role in the discovery of Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma. Earlier in his career, he was credited with discovering Viramune® (nevirapine) for HIV at Boehringer Ingelheim. He has also held senior leadership roles in research and development at LeukoSite and ProScript.

Dr. Adams has won several awards for his drug development efforts throughout his career, holds more than 40 patents from the United States Patent and Trademark Office (USPTO) and has authored more than 100 papers and book chapters in peer-reviewed journals. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He also earned a Doctor of Science, honoris causa, from McGill University in 2012.

“Julian is one of the most respected leaders in the biotechnology industry and has successfully led the global development and registration of multiple clinical programs,” said Dr. Margolin. “This is a dynamic time at Gamida Cell and as we advance the pipeline including our lead candidate, NiCord, we are excited to have Julian join us and support our objectives of expanding Gamida Cell’s global presence in the U.S. market.”

About Gamida Cell

Gamida Cell is a leader in cellular and immune therapeutics dedicated to treating patients with cancer and rare genetic diseases. The company is building a diverse pipeline based on its proprietary NAM technology platform to deliver transformative medicines to patients in need of new treatment options. To learn more about Gamida Cell, including current clinical studies, please visit www.gamida-cell.com and on Twitter, LinkedIn and Facebook.

Contacts

Pure Communications
Katie Engleman, +1-910-509-3977
katie@purecommunications.com
or
Investor Contact:
Stern Investor Relations, Inc.
Christina Tartaglia, +1-212-362-1200
christina@sternir.com

Release Summary

Julian Adams, Ph.D., joins Gamida Cell leadership team as chairman & CEO, bringing extensive experience in drug discovery and development to the role.

Contacts

Pure Communications
Katie Engleman, +1-910-509-3977
katie@purecommunications.com
or
Investor Contact:
Stern Investor Relations, Inc.
Christina Tartaglia, +1-212-362-1200
christina@sternir.com